Clinical trial
Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali
NCT00460525 · U.S. Army Medical Research and Development Command, U.S. Fed · Completed
Key facts
| NCT number | NCT00460525 |
|---|---|
| Title | Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali |
| Official title | Randomized, Controlled Phase II Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the AMA-1 Malaria Vaccine FMP2.1/AS02A Versus Rabies Vaccine in 1-6 Year Old Children in Bandiagara, Mali |
| Lead sponsor | U.S. Army Medical Research and Development Command, U.S. Fed |
| Collaborators | National Institute of Allergy and Infectious Diseases (NIAID) NIH Walter Reed Army Institute of Research (WRAIR) U.S. Fed GlaxoSmithKline Industry University of Maryland |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Plasmodium Falciparum Malaria |
| Intervention type | Biological |
| Interventions | FMP2.1/AS02A, Rabies Vaccine |
| Enrollment | 400 |
| Start date | May 1, 2007 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Apr 16, 2007 |
| Last update posted | Nov 9, 2018 |
| Countries | Mali |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: